US equities |
MU $1,086.03 ▲+3.87% NVDA $236.76 ▼-1.03% SNDK $1,719.92 ▲+3.58% SPCX $167.10 ▼-2.80% AMD $645.17 ▼-0.65% INTC $112.75 ▲+0.22% TSLA $377.21 ▼-0.91% AAPL $336.62 ▲+0.90%
FinancialContent

Twist Bioscience Corporation - Common Stock (NQ:TWST)

157.62 -9.35 (-5.60%)
Delayed Quote Updated: 2:51 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Twist Bioscience Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
News headline image
TWST Shares Rise 8% — What’s Driving The Rally? ↗
Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Twist Bioscience Q1 2026 Earnings Call Transcript ↗
Twist Bioscience Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
TWIST BIOSCIENCE CORP (NASDAQ:TWST) Reports Mixed Q1 FY2026 Results with Revenue Beat and Wider Loss ↗
Via Chartmill
News headline image
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses ↗
Twist Bioscience reports mixed Q4 earnings with a loss of 45 cents, sales of $99.01 million beating consensus. 
Via Benzinga
News headline image
Twist Bioscience Corp (NASDAQ:TWST) Stock Falls After Q4 Earnings Miss ↗
Twist Bioscience Q4 2025 earnings miss analyst estimates on revenue and EPS, triggering a sharp pre-market stock decline. 
Via Chartmill
Topics Earnings
News headline image
Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results
From Twist Bioscience Corporation
Via Business Wire
News headline image
Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Twist Bioscience ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 14, 2025 ↗
 
Via Benzinga
News headline image
This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025
From Twist Bioscience Corporation
Via Business Wire
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Cathie Wood Warns Wall Street Is Missing AI's Biggest Opportunity In Healthcare, Calling It 'Sleeper' Investment Poised For Massive Returns ↗
Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its potential. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience to Present at Baird 2025 Global Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Collaborates with Synthetic Design Lab
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors
From Twist Bioscience Corporation
Via Business Wire
News headline image
Cathie Wood's Ark Dumps Block Stock Worth $4.8 Million As Bitcoin-Heavy Company Preps Q2 Results ↗
Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday. 
Via Benzinga
News headline image
Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings ↗
Twist Bioscience beat Q3 revenue estimates, improved gross margins, and narrowed its full-year outlook while forecasting EBITDA breakeven fiscal 2026. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >